SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?


To: schzammm who wrote (667)5/6/2003 9:33:19 AM
From: nigel bates  Read Replies (1) | Respond to of 2240
 
Somehow can't see the SARS programme being a big value driver for MEDX.

Likelihood is that a MAb will be prophylactic (cf MEDI's rsv MAb), relatively expensive, and rendered unnecessary by the development of a vaccine.

If they can develop one quickly, and SARS becomes a more serious problem, it might be used for hospital staff at high risk of infection.